Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CPB1 | P15086 | 4/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19867699 | 1.00 | KDM2B (0.40) | KDM2BCYP1A2CYP2D6CPB1CPB2 | |
| SCHEMBL21047352 | 1.00 | KDM2B (0.40) | KDM2BCYP1A2CYP2D6CPB1CPB2 | |
| SCHEMBL19867707 | 1.00 | KDM2B (0.40) | KDM2BCYP1A2CYP2D6CPB1CPB2 | |
| SCHEMBL21047350 | 1.00 | KDM2B (0.40) | KDM2BCYP1A2CYP2D6CPB1CPB2 | |
| SCHEMBL21085347 | 0.83 | CPB1 (0.32) | CPB1 | |
| SCHEMBL19859663 | 0.83 | CPB1 (0.32) | CPB1 | |
| SCHEMBL19859660 | 0.83 | CPB1 (0.32) | CPB1 | |
| SCHEMBL19859658 | 0.83 | CPB1 (0.32) | CPB1 | |
| SCHEMBL22185811 | 0.79 | KDM2B (0.49) | KDM2BCPB1CPB2PHF8USP30 | |
| SCHEMBL21085843 | 0.78 | HTR6 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, FOLH1 | KDM2B 2055/4885CYP1A2 806/4885CYP2D6 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.